Lumiracoxib in the management of osteoarthritis and acute pain

@article{Bannwarth2007LumiracoxibIT,
  title={Lumiracoxib in the management of osteoarthritis and acute pain},
  author={Bernard Bannwarth and Francis Berenbaum},
  journal={Expert Opinion on Pharmacotherapy},
  year={2007},
  volume={8},
  pages={1551 - 1564}
}
Lumiracoxib is a highly selective COX-2 inhibitor with a novel chemical structure and a relatively short plasma half-life. It has been approved in > 40 countries for the symptomatic treatment of osteoarthritis and/or acute pain related to primary dysmenorrhoea and dental or orthopaedic surgery. In these conditions, lumiracoxib has proved to be as effective as standard doses of conventional NSAIDs and other COX-2 selective inhibitors (coxibs). According to the Therapeutic Arthritis Research… 
Safety of the Nonselective NSAID Nabumetone
TLDR
Limited comparative data suggest that nabumetone offers a GI tolerability profile similar to that of cyclo-oxygenase-2 selective NSAIDs (coxibs), and there is no particular concern about the nephrotoxic and hepatotoxic potential of nabumETone.
Ibuprofen: pharmacology, efficacy and safety
TLDR
Paediatric use of ibuprofen is reviewed and the main results are that the drug is relatively safe and effective as a treatment of acute pain and fever, and is probably more effective than paracetamol as an antipyretic.
Peripheral Synergistic Interaction Between Lidocaine and Lumiracoxib on the 1% Formalin Test in Rats
TLDR
Data suggest that low doses of the lumiracoxib-lidocaine combination can interact synergistically at the peripheral level and therefore this drug association may represent a therapeutic advantage for the clinical treatment of procedural or inflammatory pain.
The search for new COX-2 inhibitors: a review of 2002 – 2008 patents
TLDR
Structural analogues of the COX-2 inhibitors celecoxib and valdecoxib, and novel potential pyridazine, triazole, indole and thione derivatives emerge as promising leads for the treatment of inflammation, pain and other diseases.
In Vitro Metabolic Activation of Lumiracoxib in Rat and Human Liver Preparations
TLDR
These findings demonstrate that lumiracoxib is subject to P450-mediated bioactivation in both rat and human liver preparations, leading to the formation of a reactive intermediate analogous to species generated during the metabolism of diclofenac.
A genome-wide study identifies HLA alleles associated with lumiracoxib-related liver injury
TLDR
A case-control genome-wide association study offers the potential to improve the safety profile of lumiracoxib by identifying individuals at elevated risk for liver injury and excluding them from lumirACoxib treatment.
Lumiracoxib metabolism in male C57bl/6J mice: characterisation of novel in vivo metabolites
TLDR
No evidence was obtained in the mouse for the production of the downstream products of glutathione conjugation such as mercapturates, suggesting that the metabolism of the drug via quinone–imine generating pathways is not a major route of biotransformation in this species.
The pharmacokinetics and metabolism of lumiracoxib in chimeric humanized and murinized FRG mice
Investigational pharmacology for low back pain
TLDR
The anatomy and pathogenesis of disease processes that contribute to low back pain are summarized, and the scientific rationale for investigational pharmacology is explained, and emerging compounds in late development are highlighted.
Structure-toxicity relationship and structure-activity relationship study of 2-phenylaminophenylacetic acid derived compounds.
...
1
2
3
...

References

SHOWING 1-10 OF 76 REFERENCES
Gastrointestinal tolerability of lumiracoxib in patients with osteoarthritis and rheumatoid arthritis.
Efficacy of Lumiracoxib in Osteoarthritis: A Review of Nine Studies
TLDR
Lumiracoxib provided consistent reductions in OA pain intensity and improvements in the patient's global assessment of disease activity and functional status, and was superior to placebo and similar to the active comparators tested.
Gastroduodenal safety and tolerability of lumiracoxib compared with Ibuprofen and celecoxib in patients with osteoarthritis.
TLDR
In patients with OA, lumiracoxib 200 mg or 400 mg qd was associated with a significantly lower risk of gastroduodenal ulceration than ibuprofen 800 mg tid, and was similar to celecoxib 200mg qd.
Clinical pharmacology of lumiracoxib, a second-generation cyclooxygenase 2 selective inhibitor
TLDR
Clinical studies support a once-daily dosing regimen of lumiracoxib, a novel COX-2 selective inhibitor with improved biochemical selectivity over that of currently available coxibs, which is structurally distinct from other drugs in the class and has weakly acidic properties.
Acetaminophen or NSAIDs for the treatment of osteoarthritis.
  • B. Bannwarth
  • Medicine
    Best practice & research. Clinical rheumatology
  • 2006
Lumiracoxib is effective in the treatment of osteoarthritis of the knee: a prospective randomized 13-week study versus placebo and celecoxib
TLDR
Lumiracoxib is a well-tolerated and effective treatment option for OA of the knee, providing pain relief and improved functional status with efficacy superior to placebo and similar to celecoxib.
Efficacy and tolerability of lumiracoxib versus placebo in patients with osteoarthritis of the hand.
TLDR
Lumiracoxib significantly improved overall OA pain intensity in the target hand versus placebo, with a tolerability profile similar to placebo, and 200 and 400 mg od were effective and well tolerated treatments for OA of the hand.
Licofelone--clinical update on a novel LOX/COX inhibitor for the treatment of osteoarthritis.
TLDR
The emerging clinical data for licofelone indicate that it is an effective and well-tolerated therapy that could offer safety advantages over current treatment options, and that it could be suitable for the long-term treatment of a broad spectrum of patients with OA.
...
1
2
3
4
5
...